If your medical spa or aesthetic practice relies on major dermal filler brands, a major legal filing in federal court deserves your attention. On July 21, 2026, Allergan, Inc. and its parent company, AbbVie, filed a patent-infringement lawsuit against Galderma Group AG and its affiliates in the U.S. District Court for the Northern District of Texas.
Unlike typical medical litigation, this high-stakes battle between the makers of Juvéderm and Restylane isn’t about the safety of the product inside the syringe. Instead, it focuses entirely on the design of the syringe itself.
For aesthetic injectors, practice owners, and industry stakeholders, understanding the nuances of this case is essential for separating sensationalized headlines from actual operational risk.
The Core of the Dispute: Design Patents Under Fire
The lawsuit centers on Galderma’s newly redesigned, next-generation Restylane syringe. Galderma rolled out the design globally in February 2026 after receiving regulatory clearances in the United States, Canada, and the European Union. The company highlighted that the new syringe was developed alongside aesthetic practitioners to offer enhanced precision, comfort, and a cushioned finger grip.
However, AbbVie and Allergan claim that this ergonomic upgrade crosses the line into intellectual property theft. The complaint alleges that the silhouette and ornamental features of Galderma’s new syringe infringe upon five U.S. design patents held by Allergan for its Juvéderm delivery systems.
Specifically, the lawsuit challenges the visual similarity of:
- The contours of the curved finger grips (flanges)
- The geometry and shape of the plunger head
- The distinct contours surrounding the syringe barrel
- The overall proportions and aesthetic silhouette of the device
Ornamental vs. Functional: A Quick Explainer
To appreciate how a company can claim ownership over the appearance of a medical syringe, it helps to understand the difference between the two primary types of U.S. patents:
- Utility Patents: These protect how an invention works, its mechanical operation, chemical composition, or functional utility.
- Design Patents: These protect only the ornamental appearance or visual configuration of an article of manufacture.
Allergan’s lawsuit is built entirely on design patents. The company is not arguing that Galderma copied its cross-linked hyaluronic acid formulation, manufacturing technology, or mechanical delivery mechanics. They are arguing that the external visual identity of the new Restylane syringe mimics the distinct, protected look of the Juvéderm syringe so closely that it constitutes infringement.
What Allergan is Seeking
Because the complaint was only recently filed, these claims remain unproven until a court rules or the parties reach a settlement. However, the remedies Allergan is seeking could have commercial ripple effects if granted:
- A Permanent Injunction: Allergan wants the court to bar Galderma from importing, selling, or marketing the newly designed syringe in the United States.
- Financial Remedies: The plaintiffs are asking for the profits Galderma yields from the disputed syringe design, along with enhanced damages for what they argue is deliberate infringement.
Galderma has the opportunity to challenge these claims by disputing visual similarity, questioning the validity or scope of Allergan’s design patents, or proving that the features are primarily functional rather than ornamental.
What Aesthetic Practices and Injectors Should Do Now
When corporate titans clash over intellectual property, medical spa owners and clinical teams must assess their immediate risks.
1. Do Not Panic Over Product Safety or Recalls
It is crucial to communicate clearly with your staff and patients: this is not a product safety issue. There are no clinical warnings, safety concerns, or formulation defects associated with either Restylane or Juvéderm stemming from this case. Patients who have received these treatments do not need to be alarmed, and practices do not need to pause treatments due to clinical risk.
2. Monitor Your Supply Chain
At this stage of a patent lawsuit, operations continue as normal. An injunction has not been granted, meaning Galderma can legally distribute its products. However, if the court eventually sides with Allergan or grants a preliminary injunction, Galderma could be forced to temporarily pause distribution or revert to its previous syringe architecture in the U.S. Keep an open line of communication with your product representatives to stay ahead of any unforeseen inventory adjustments.
3. Educate Your Staff
News of corporate lawsuits frequently mutates into misleading social media rumors regarding product bans or health scares. Ensure your injectors and patient coordinators understand that this is a commercial dispute over “finger flanges and plunger shapes,” not a medical scandal. Having a factual script ready will protect your practice’s patient relationships and clinical reputation.
We will continue tracking Allergan v. Galderma as it moves through the discovery phase in Texas. For now, practices should focus on maintaining excellent patient care and ensuring their teams remain informed by reality rather than rumors.
Questions about how this dispute could affect your practice’s inventory, vendor contracts, or patient communications? Contact Lengea Law to speak with an attorney.